Onyx Pharmaceuticals – Changing the Way Cancer is Treated ®
Description: Onyx Pharmaceuticals is committed to developing therapeutics that improve the lives of individuals with cancer. Our lead product is Nexavar® (sorafenib) tablets, an oral, targeted therapy for the treatment of patients with liver cancer and advanced kidney cancer.
Keywords: Onyx Pharmaceuticals, biopharmaceutical company, cancer therapeutics, Nexavar, sorafenib, ONX 0801, ONX 0803, ONX 0805, oral targeted therapy, liver cancer treatment, advanced kidney cancer treatment, liver cancer, kidney cancer, non-small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, cell cycle kinase inhibitor
Tags: onyx, pharma, pharmaceuticals, cancer, treated, way, changing, present, conference, onx, overview, company, annual, healthcare, health, cowen, announces, care, terms, design, use, global, plans, european, phase, study, registration, amend, capital, barclays, focus, website, liver, kidney, nexavar, corporate, treatment, sorafenib, cell, information,
Onyx-pharma.com
|
Content Revalency:
Title: 66.67%
Description: 18.75%
Keywords: 50.00% | Document size: 15,586 bytes
More info: Whois - Trace Route - RBL Check |
|
| ONYX-PHARMA.COM - Site Location | |
| Country/Flag | |
| City/Region/Zip Code | Louisville, Colorado, 80027 |
| Organization | Abovenet Communications |
| Internet Service Provider | Abovenet Communications |
| ONYX-PHARMA.COM - Domain Information | |
| Domain | ONYX-PHARMA.COM [ Traceroute RBL/DNSBL lookup ] |
| Registrar | MARKMONITOR INC. MarkMonitor, Inc. |
| Registrar URL | http://www.markmonitor.com |
| Whois server | whois.markmonitor.com |
| Created | 11-Oct-2010 |
| Updated | 09-Nov-2015 |
| Expires | 11-Oct-2017 |
| Time Left | 0 days 0 hours 0 minutes |
| Status | clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited clientTransferProhibited https://icann.org/epp#clientTransferProhibited clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited clientUpdateProhibited (https://www.icann.org/epp#clientUpdateProhibited) clientTransferProhibited (https://www.icann.org/epp#clientTransferProhibited) clientDeleteProhibited (https://www.icann.org/epp#clientDeleteProhibited) |
| DNS servers | NS1.MARKMONITOR.COM 64.124.69.50 NS2.MARKMONITOR.COM 64.124.69.52 NS3.MARKMONITOR.COM 217.68.151.240 NS4.MARKMONITOR.COM 217.68.151.241 NS5.MARKMONITOR.COM 202.167.230.240 NS6.MARKMONITOR.COM 202.167.230.241 NS7.MARKMONITOR.COM 64.124.69.51 ns7.markmonitor.com 64.124.69.51 ns6.markmonitor.com 202.167.230.241 ns3.markmonitor.com 217.68.151.240 ns4.markmonitor.com 217.68.151.241 ns2.markmonitor.com 64.124.69.52 ns5.markmonitor.com 202.167.230.240 ns1.markmonitor.com 64.124.69.50 |
| ONYX-PHARMA.COM - DNS Information | |
| IP Address | 64.124.14.63 ~ Whois - Trace Route - RBL Check |
| Domain Name Servers | ns1.markmonitor.com 64.124.69.50 ns7.markmonitor.com 162.88.61.19 ns2.markmonitor.com 162.88.60.13 ns4.markmonitor.com 162.88.60.15 ns6.markmonitor.com 162.88.60.17 ns5.markmonitor.com 162.88.61.17 ns3.markmonitor.com 162.88.61.15 |
| Mail Exchange | bh.markmonitor.com |
| Site Response Header | |
| Response | HTTP/1.1 301 Moved Permanently |
| Server | Microsoft-IIS/7.0 |
| Date | Fri, 15 Apr 2011 06:49:18 GMT |
| Content-Type | text/html; charset=UTF-8 |
| Cookie | CFTOKEN=99181158;path=/ |